Compare Chipotle Mexican Grill, Inc. (CMG) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Crispr Therapeutics AG — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.68 (market cap $40.49B), while Crispr Therapeutics AG trades at $53.89 (market cap $5.23B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 7.7× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| CMG | CRSP | |
|---|---|---|
Market Cap | $40.49B | $5.23B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $76.78 |
52-Week Low | $28.17 | $44.34 |
Enterprise Value | $45.24B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.25, up 0.34% on the day, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds from a recent salmonella outbreak linked to jalapeños, contributing to a 12.64% weekly drop. Fundamentally, revenue growth remains robust, reaching $11.93B in 2025, with strong profitability metrics including a 49.56% ROE. Analyst consensus is overwhelmingly bullish with a $42.17 price target, though technical indicators show selling pressure with key support at $32.
The outlook for CMG balances strong fundamentals against near-term operational risks. Wall Street's buy ratings (70.15%) reflect confidence in long-term growth, but recent food safety issues and declining net income margins pose immediate challenges. Investors should weigh the company's consistent revenue trajectory against potential volatility from ongoing outbreaks and rising costs.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
